PEDIATRICS Vol. 96 No. 6 December 1995, pp. 1040-1045
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Seaman, D. E.
Right arrow Articles by Manzi, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Seaman, D. E.
Right arrow Articles by Manzi, S.

Antiphospholipid Antibodies in Pediatric Systemic Lupus Erythematosus

David E. Seaman MD1, A. Vincent Londino Jr MD2, C. Kent Kwoh MD3, Thomas A. Medsger Jr MD1, and Susan Manzi MD, MPH1

1 Department of Medicine, Division of Rheumatology and Clinical Immunology, Graduate School of Public Health, University of Pittsburgh School of Medicine
2 Department of Medicine, Division of Rheumatology and Clinical Immunology, Department of Pediatrics, Graduate School of Public Health, University of Pittsburgh School of Medicine
3 Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh School of Medicine

Objective. Antiphospholipid antibodies (aPLs) have been extensively studied in adults with systemic lupus erythematosus (SLE) and have been associated with arterial and venous thrombosis, thrombocytopenia, neurologic disorders, and recurrent fetal loss. In contrast, very little is known about the frequency and clinical significance of aPLs in pediatric SLE. This study was designed to determine the frequency of aPLs in pediatric SLE and the temporally associated clinical manifestations.

Design. We studied 29 consecutive patients with onset of SLE in childhood seen in the Pediatric Rheumatology Clinic at the University of Pittsburgh, Children's Hospital, between 1985 and 1992. We defined aPL as the presence of a lupus anticoagulant (LAC), immunoglobulin G or immunoglobulin M anticardiolipin antibodies (aCLs), or a biologic false-positive serologic test for syphilis determined by a VDRL test. Clinical manifestations were temporally correlated to the presence of aPLs if they occurred within 6 months.

Results. Overall, 19 (65%) of 29 children with SLE had one of the three laboratory abnormalities defining aPL. LAC was detected in 16 (62%) of 26, aCL in 18 (66%) of 27, and false-positive VDRL test results in 11 (39%) of 28. Twenty-five of the 29 patients had all three tests performed. In 10 patients, all three tests were abnormal. The presence of thrombosis in 7 patients (4 venous, 2 arterial, and 1 both) was associated with a positive aPL, specifically aCL. The presence of an aPL was significantly associated with anti-double-stranded DNA antibodies, but not with neuropsychiatric manifestations or with thrombocytopenia. The presence of an aCL was significantly associated with hemolytic anemia. A prolonged prothrombin time, in the setting of an LAC (all with a prolonged activated partial thromboplastin time), was associated with life-threatening disease in 6 of 15 patients.

Conclusion. Sixty-five percent of 29 consecutive pediatric patients with SLE had evidence of aPL. The presence of aPL, specifically aCL, was significantly associated with thrombotic events. The presence of a prolonged prothrombin time in the setting of an LAC may be a marker of more serious disease in pediatric SLE.

Submitted on September 6, 1994
Accepted on December 27, 1994




This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
E. Descloux, I. Durieu, P. Cochat, D. Vital Durand, J. Ninet, N. Fabien, and R. Cimaz
Paediatric systemic lupus erythematosus: prognostic impact of antiphospholipid antibodies
Rheumatology, February 1, 2008; 47(2): 183 - 187.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
T. Avcin and E. Silverman
Review: Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome
Lupus, August 1, 2007; 16(8): 627 - 633.
[Abstract] [PDF]

Home page
 LupusHome page
Y Uziel, N Gorodnitski, M Mukamel, S Padeh, R Brik, J Barash, D Mevorach, Y Berkun, T Tauber, J Press, et al.
Lupus around the World: Outcome of a national Israeli cohort of pediatric systemic lupus erythematosus
Lupus, February 1, 2007; 16(2): 142 - 146.
[Abstract] [PDF]

Home page
 Pediatr. Rev.Home page
B. S. Gottlieb and N. T. Ilowite
Systemic Lupus Erythematosus in Children and Adolescents.
Pediatr. Rev., September 1, 2006; 27(9): 323 - 330.
[Full Text] [PDF]

Home page
 LupusHome page
D M Levy, M P Massicotte, E Harvey, D Hebert, and E D Silverman
Thromboembolism in paediatric lupus patients
Lupus, October 1, 2003; 12(10): 741 - 746.
[Abstract] [PDF]

Home page
 LupusHome page
T Avcin, R Cimaz, and P. Meroni
Letter to the Editor
Lupus, December 1, 2001; 10(12): 897 - 898.
[PDF]

Home page
 LupusHome page
S Miyagawa, Y Uchida, K Taira, M Higuchi, K Hashimoto, A Yoshioka, and T Shirai
Autoantibody responses to cardiolipin and DNA in infancy: association with lymphocytic panniculitis
Lupus, October 1, 2000; 9(8): 637 - 640.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
M. Bonduel, G. Sciuccati, M. Hepner, A. F. Torres, G. Pieroni, and J. P. Frontroth
Prethrombotic Disorders in Children With Arterial Ischemic Stroke and Sinovenous Thrombosis
Arch Neurol, August 1, 1999; 56(8): 967 - 971.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
J M Gloor
Lupus nephritis in children
Lupus, November 1, 1998; 7(9): 639 - 643.
[Abstract] [PDF]

Home page
 LupusHome page
A Gedalia, J F Molina, C O Garcia, S Doggett, L R Espinoza, and A E Gharavi
Anticardiolipin antibodies in childhood rheumatic disorders
Lupus, October 1, 1998; 7(8): 551 - 553.
[Abstract] [PDF]